Pfizer Looking To Tap Into Asia’s Emerging Oncology Market
This article was originally published in PharmAsia News
Executive Summary
Looking to increase global market share, Pfizer has established a business unit devoted to oncology within its worldwide pharmaceutical group, in part, to strengthen research investment on cancers common in Asia, including liver, esophagus and nasopharynx